SAVE-Care (Sodium Glucose Cotransporter-2 Inhibitors [SGLT2i] As Novel Gout Care) Trial

PHASE4Not yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 15, 2025

Primary Completion Date

March 2, 2026

Study Completion Date

March 2, 2026

Conditions

Gout and Hyperuricemia

Interventions

DRUG

Empagliflozin 10 mg

For the empagliflozin arm, participants will take 10 mg daily.

DRUG

Placebo

Participants in the placebo arm will take a placebo daily.

All Listed Sponsors

lead

Massachusetts General Hospital

OTHER